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Abstract  
 
Objectives – To evaluate perceived patient burden and acceptability of whole body MRI 
(WB-MRI) compared to standard staging investigations, and identify predictors of reduced 
tolerance. 
Methods – Patients recruited to multi-centre trials comparing WB-MRI with standard staging 
scans for lung and colorectal cancer were invited to complete two questionnaires: a baseline 
questionnaire at recruitment, measuring demographics, comorbidities, and distress; and a 
follow-up questionnaire after staging, measuring recovery time, comparative acceptability/ 
satisfaction between WB-MRI and CT (colorectal cancer) and PET-CT (lung cancer), and 
perceived scan burden (scored 1 low to 7 high).  
Results – 115 patients (median age 66.3 years; 67 males) completed follow-up and 103 
baseline questionnaires. Sixty-nine (63.9%) reported “immediate” recovery from WB-MRI 
and 73 (65.2%) judged it “very acceptable”. Perceived WB-MRI burden was greater than for 
CT (p<0.001) and PET-CT (p<0.001). High distress and co-morbidities were associated with 
greater WB-MRI burden in adjusted analyses, with deprivation only approaching significance 
(adjusted regression Beta=0.223, p=0.025; Beta=0.191, p=0.048; Beta = -0.186, p=0.059 
respectively). Age (p=0.535), gender (p=0.389), ethnicity (p=0.081) and cancer type 
(p=0.201) were not predictive of WB-MRI burden.  
Conclusions: WB-MRI is marginally less acceptable and more burdensome than standard 
scans, particularly for patients with pre-existing distress and comorbidities. 
Advances in knowledge:  This research shows that WB-MRI scan burden, although low, is 
higher than for current staging modalities among patients with suspected colorectal or lung 
cancer. Psychological and physical co-morbidities, adversely impact on patient experience of 
   
   
WB-MRI. Patients with high distress or comorbid illness may need additional support to 
undergo a WB-MRI. 
KEYWORDS: whole- body MRI; oncology; PET-CT; CT; patient satisfaction  
   
   
Introduction 
Patients diagnosed with cancer must be staged accurately prior to treatment decisions. In 
particular it is imperative to detect metastatic disease, as this impacts considerably on 
therapeutic approach. Standard staging pathways are often complex, time consuming and 
involve several different imaging modalities, potentially adding to physical and psychological 
burden of patients with known or suspected cancer.
1
  
 
Recent data suggests whole body MRI (WB-MRI) has potential as an “all-in-one” staging 
investigation that at least matches and possibly betters the accuracy of conventional 
investigations for detecting metastatic disease.
2;3
 One critical but often neglected aspect 
influencing adoption of any new technology is patient experience. Low patient acceptability 
reduces adherence, which diminishes diagnostic impact, even when superior to existing tests.  
Uptake of bowel cancer screening colonoscopy is an example where perceived test burden 
impacts directly to reduce participation.
4
  
 
WB-MRI has several attributes that can impact negatively on patient experience. Although 
protocols are dependent upon the underlying disease process, the scan acquisition time for 
cancer staging is typically around  45 to 60 minutes, and considerably longer than CT or even 
PET-CT, with image acquisitions taking seconds or minutes respectively (although patient 
experience will be influenced by the total examination time, rather than just time taken for 
image acquisition).  Moreover, MRI scanners are noisy and require full body and head 
immersion inside a relatively narrow “tube”, often necessitating closely applied receiver coils 
that restrict movement. Existing data show that 5 to 30% of patients experience distress both 
in anticipation of MRI, and during the scan itself.
5-7
 Severe claustrophobia terminates 
scanning in 1 to 15%,
8
 and even if the patient completes the scan, distress precipitates motion 
   
   
artefacts that degrade image quality and impair diagnostic accuracy.
9
 Furthermore, post scan 
anxiety
6
 can engender MRI fear or phobia.
10
 
Quantifying patient “distress” around diagnostic imaging is complex and has been expressed 
as procedural “burden”, a composite variable based on rating the level of physical and 
psychological discomfort related to scanning.  Shortman et al.
11
 found the perceived burden 
of PET-MRI was greater than PET-CT; burden was related to scan preference with an over-
all preference for PET-CT. A recent qualitative interview study reported that WB-MRI was 
perceived by some as more challenging than PET-CT and CT.
12
 To date, predictors of 
increased patient burden before or during WB-MRI have received little attention. Such 
knowledge may identify those who require additional psychological support in advance or 
physical interventions such as sedation in order to complete scanning.
13
   
The purpose of this study was to evaluate the perceived patient burden and acceptability of 
whole body MRI compared to standard staging investigations, and to identify predictors for 
reduced patient tolerance. 
 
Methods and materials 
Participants 
Patients recruited prospectively to two ongoing clinical trials, comparing the diagnostic 
accuracy and cost-effectiveness of WB-MRI with standard tests for staging colorectal and 
lung cancer, were invited to participate in the current study. Patients were eligible for the 
main trials if they were recently diagnosed or highly suspected of colorectal (Streamline C) or 
non-small cell lung cancer (Streamline L), such that they were referred for staging 
investigations. Written consent was obtained for participation in the current study. As part of 
the trial protocol, patients underwent WB-MRI staging in addition to all standard staging 
investigations such as CT and PET-CT. The full trial protocol details have been previously 
   
   
reported.
14
 The WB-MRI required intravenous cannulation for the administration of 
gadolinium. Full ethical permission was given by Camden and Islington National Research 
Ethics Service (NRES) on 03/10/2012, project numbers: 12/LO/1176 (Streamline C) and 
12/LO/1177 (Streamline L). 
Between March 2013 and July 2015, 392 consecutive patients recruited to the main trials 
were given the option to participate in either an interview study (reported elsewhere
12
) or the 
current questionnaire study as part of the informed consent process for the main trials. Three 
hundred and fifty (89.3%) consented.  The interview study investigated patients’ experiences 
of staging investigations.  
 
Initially, patients (n=91) were recruited to the interview study, previously reported.
12
 
Thereafter patients were recruited exclusively to the questionnaire study presented here. None 
of the patients who took part in the present study took part in the prior interview study. 
The full recruitment pathway and reasons for exclusion is presented in Figure 1. A total of 
115 patients completing the follow up questionnaires (see below) were included in the 
analyses. 
Procedures 
Patients were asked to complete two questionnaires. The first (baseline) questionnaire was 
mailed to patients within 2 days of being registered for the Streamline trials, completed 
around the time patients were undergoing their staging investigations, and returned using a 
stamped addressed reply envelope.  A second “post staging” questionnaire was posted one 
month after the baseline questionnaire was administered and was completed after all staging 
investigations were completed. Patients were paid £20 for participation, which was continued 
until a minimum of 100 patients had returned both questionnaires (50 for Streamline L and 50 
for Streamline C)-see power calculation below.  
   
   
Questionnaire content 
The following data were collected in the baseline questionnaire: 
(i) Emotional Distress: The 12 item General Health Questionnaire (GHQ-12)15 was 
used to assess psychological distress. An example item is, “In the last three 
months have you….been able to concentrate on whatever you’re doing”. Using 
the GHQ-12 binary coding method (0,0,1,1), a mean sum score (if at least 50% of 
items were answered) was created ranging from 0 to 12. A score of 4 or higher is 
considered indicative of significant distress levels.
16
 
(ii) Co-morbidity: Patients were asked about their current and recent physical health 
and mental well-being. Patients were asked to report (“yes” or “no”) whether they 
had any of the following diseases: heart or vascular disease, diabetes, epilepsy, 
stroke, arthritis, asthma, mental or emotional disorder. There was also an option to 
provide details of other illness. A response of “yes” to any illness was coded and a 
dichotomous “co-morbidity” variable was created whereby the presence of one or 
more comorbid illness was reported: either yes or no. The presence of a mental or 
emotional disorder was excluded as this was captured in the GHQ-12.  Self-report 
measures of comorbidity have been shown to be valid
17;18
 and offer a more cost-
effective method of data collection than medical record-based measures. 
(iii) Demographics: Patients were asked their age, gender and ethnicity.  Missing 
demographic data on age and gender as well as zip code data were supplied via 
the central trial database (with patient consent). Zip code data were used to 
calculate an area based deprivation score for each individual using the 2010 IMD 
scale,
19
categorised into quintiles from 1 (highest levels of deprivation) to 5 
(lowest).  
 
   
   
Part of the follow up questionnaire asked patients about their comparative experience of WB-
MRI and staging CT chest, abdomen and pelvis (standard scan) if recruited to Streamline C, 
or to PET-CT (standard scan) if recruited to Streamline L. The following data were captured. 
(i) Scan recovery, satisfaction and acceptability: Patients rated their post scan 
recovery on a 9-point scale ranging from “immediate” to “a week”. Data were 
collapsed into 3 categories “immediate”, “up to 30 minutes” and “over 30 
minutes” for analysis.  Patients also rated how satisfied they were with the 
information received before scanning, communication and departmental facilities, 
as well as the overall acceptability of scans, on a scale of 1(very dissatisfied/ not 
at all acceptable) to 4 (very satisfied/ very acceptable).  
 
(ii) Scan burden was quantified using a questionnaire adapted from one previously 
used to assess acceptability of colonoscopy
20;21
 (Appendix A). Patients completed 
the 26 item scale for both WB-MRI and standard scans, describing their 
experiences by ticking agreement on a 1-7 Likert scale where 1 and 7 were 
anchored to bi-polar statements related to scan discomfort (13 items), worry (6 
items), and satisfaction (7 items).  An example discomfort item was 1=“not 
claustrophobic” to 7= “claustrophobic”.  Sub scores for discomfort, worry and 
satisfaction scales were computed from the mean of completed items (if less than 
50% of items were completed, the response was coded as missing). A total score 
“scan burden” was computed by taking the mean of discomfort, worry and reverse 
scored satisfaction sub-scales with higher scores equating to greater scan burden.   
Power calculation 
Power (G*Power - version 3
22
) was based on rejecting the null hypothesis that there was no 
significant difference in perceived burden of WB-MRI when compared to standard staging 
   
   
(related t-test). Assuming a medium effect size (d=0.5), alpha of 0.05 and 95% power,
23
 a 
minimum number of 90 patients were required across the two study cohorts (45 in Streamline 
C and 45 in Streamline L). An effect size of 0.5 is considered the minimal important 
difference (MID) in quality of life measures,
24
 where MID is defined as the smallest 
difference that patients view as important (beneficial or harmful), and would result in a 
doctor considering a change in the patient’s management.25 
 
Statistical Analysis 
Analysis was performed using SPSS version 22.  Differences in demographic and 
psychological characteristics between Streamline L and Streamline C cohorts were assessed 
using the Mann Whitney U test, and Chi Square or Fisher’s Exact tests (if 20% or more of the 
cells in the contingency table had expected counts of less than 5) as appropriate. Related 
samples Wilcoxon sign tests were used to assess differences between WB-MRI vs CT/ PET-
CT in terms of scan recovery time, scan acceptability, and satisfaction with scan-related 
information, facilities, communication and scan burden. Linear regression tested the 
predictive value for WB-MRI scan burden of data collected in the baseline questionnaire. 
Individual predictors were entered in unadjusted analyses and those items achieving 
statistical significance were then entered into a multivariate analysis.  Statistical significance 
was assigned at the 5% level, two-tailed. 
 
Results:  
Of the 350 patients agreeing to participate in the questionnaire or separate interview study, 
rates of consent were significantly higher among patients recruited to Streamline L compared 
to those recruited to Streamline C; (93.1% vs. 85.8%; X
2
=5.451, df=1; p=0.020), see Figure 
   
   
1. There were no differences in basic demographics between those who consented compared 
to those who did not (see Appendix B).  
 
 In total, 214 patients were sent both questionnaires of whom 99 were excluded leaving 115 
for analysis. Reasons for exclusion were non response (n=71), returned baseline 
questionnaire only (n=27), and trial withdrawal (n=1) (Figure 1).  Patients with lower levels 
of deprivation were more likely to return the post staging questionnaire (linear chi-
square:7.113, df=1; p=0.008). There were no differences in sex (p=0.059), age (p=0.676) or 
cancer type (Chi-square=0.442; df=1; p=0.506), between those who did, and did not return 
the post staging questionnaire (see Appendix C). 
 
Full demographics of the 115 patients are shown in Table 1. Overall, 103 patients (median 
age 66; 58 males) completed both questionnaires and 12 (median age 60; 9 males) completed 
the post staging questionnaire only. Sixty one patients were recruited to Streamline C and 54 
to Streamline L. Female patients recruited to Streamline C (n=24) were significantly younger 
than those recruited to Streamline L (n= 24) (median age 60 vs 73 years; p=0.003), with no 
significant age difference between males (66 years, n=37 vs 66 years, n=30, respectively; 
p=0.480). 
 
Patients recruited to Streamline L were significantly more likely to report additional 
comorbidity than those recruited to Streamline C (66.7% vs. 40.4%, p=0.008) with no 
significant differences for the presence of baseline psychological distress between the two 
trial cohorts (see Table 1).  
Post-scan patient recovery and scan acceptability  
   
   
Patients’ responses to scan recovery time and overall acceptability are summarised in Table 
2. There were no significant differences in recovery time after WB-MRI compared to CT/ 
PET-CT, with 63.9% of patients who completed this item (n=69) reporting “immediate” 
recovery following WB-MRI compared with 65.1% following CT/PET-CT (see Table 2). 
However scan acceptability ratings were significantly lower for  WB-MRI compared to both 
CT and  PET-CT. Patients’ satisfaction with information before the scan and facilities, 
together with communication during the scan and were all high and not significantly different 
between WB-MRI and either CT or PET-CT (Table 2). 
Scan burden 
In general patients tolerated all the imaging modalities well and reported low levels of scan 
burden.  Mean ratings for scan discomfort and worry ranged from 1.63 to 2.65 where 7 
represents maximum discomfort or worry. Mean satisfaction scores ranged from 6.25 to 6.53 
where 7 represents maximum satisfaction.  
However mean burden scores for WB-MRI were significantly greater than those of PET-CT 
and CT (see Table 3). The higher burden of WB-MRI was mainly due to items related to 
“discomfort”, although there were also significant differences in relation to “satisfaction”.  
Questionnaire items related to “worry” were only less favourable for WB-MRI in comparison 
to CT, and did not differ for WB-MRI in comparison to PET-CT. Specific items within the 
discomfort sub-scale particularly relevant to WB-MRI , showed WB-MRI conferred 
significantly greater feelings of claustrophobia than both CT (means scores 2.81 vs. 1.51; 
p<0.001) and PET-CT (mean scores 3.04 vs 1.98; p<0.001); greater burden from scan-related 
noise compared with both CT (means 2.84 vs. 1.73; p<0.001) and PET-CT (2.85 vs. 1.63; 
p<0.001). In general, the intravenous injections required for each of the three scan types 
   
   
resulted in low levels of discomfort which did not differ between scan type (WB-MR vs CT: 
1.59 vs 1.56, p=0.637; WB-MRI vs PET-CT: 1.86 vs 1.73, p=0.225).  
WB-MRI burden was not rated differently between those recruited to Streamline C or 
Streamline L cohorts (see below). In contrast patients recruited to Streamline L reported 
significantly more worry and discomfort during PET-CT compared to the equivalent ratings 
for CT by those recruited to Streamline C; (worry 2.52 vs 2.00; p<0.001; discomfort 2.04 vs 
1.63: p<0.001). 
Predictors of WB-MRI scan burden. 
The regression analysis for predictors of WB-MRI scan burden showed that the presence of 
co-morbidity, psychological distress and  deprivation were significant predictors in 
unadjusted analysis (Beta=0.242, p=0.015, Beta=0.305, p=0.002 and Beta=-0.265, p=0.005 
respectively), with age, gender, and cancer type non-significant predictors and ethnicity 
approaching significance (Beta=0.059, p=0.535; Beta = 0.083, p=0.389; Beta=-0.122, 
p=0.201;  Beta= -0.179, p=0.081). In the adjusted analyses only psychological distress and 
presence of comorbidities remained significantly predictive (Beta=0.223; p=0.025; 
Beta=0.191, p=0.048) with deprivation approaching significance (Beta = -0.186, p=0.059). 
 
 
Discussion  
As data supporting WB-MRI for cancer staging accumulates
2;3
 and the technology enters 
clinical practice, it is important to understand patient experience and overall acceptability. 
Cancer patients are vulnerable and may already be suffering significant distress
1;26
 which 
may impact on the acceptability of potentially unpleasant staging investigations. 
   
   
We investigated patient experience and overall acceptability of WB-MRI compared to 
standard PET CT and CT in two cohorts of patients recently diagnosed or highly suspected of 
lung or colorectal cancer. While standard scans can distress patients,
27;28
 we hypothesised that 
patients would find WB-MRI less acceptable given its attributes. This hypothesis was 
informed by related qualitative work that indicated some (but not all) patients found the scan 
a challenge and comparatively more so than CT and PET-CT scans.
12
   
In reality, our data show that, in general, patients tolerate WB-MRI well; absolute discomfort 
and worry were low, and satisfaction was high. However, the burden of WB-MRI was 
significantly greater than for both PET-CT and CT. This differential was particularly 
apparent when compared to CT, the standard first line staging investigation for patients with 
colorectal cancer. We also found evidence that PET-CT burden was greater than for CT, 
particularly for items pertaining to discomfort and worry, although, as noted below, the 
higher prevalence of comorbidities in the lung cancer patient cohort may have influenced 
their tolerance of PET-CT.  
Although our findings are perhaps intuitive given the known attributes of the tests, they are 
actually at odds with the findings of Adams et al.,
29
 who compared WB-MRI with CT in 
patients undergoing lymphoma staging. Adams found that patients found WB-MRI more 
“friendly”, less unpleasant, and less “worrisome” than CT, attributing the relative negative 
evaluation of CT to more invasive preparation - patients had an intravenous line placed and 
consumed oral contrast. In our study mean patient age (65 years) was considerably higher 
than the 50 years reported by Adams et al. furthermore, the Streamline trial WB-MRI 
protocols required IV gadolinium, which may also help explain discrepant findings.    
We investigated factors that might predict worsened scan experience. As would perhaps be 
expected in a cohort of patients undergoing investigations for suspected or newly diagnosed 
   
   
cancer, a significant proportion reported high level of baseline distress, and as predicted, this 
distress was associated with subsequent higher WB-MRI burden. Furthermore, patients with 
additional co-morbidity experienced greater burden. A recent review suggests that co-
morbidities can reduce cancer survival and co-morbidity is associated with receiving sub-
optimal treatment.
30
 Our data suggests comorbidity influences the tolerability of WB-MRI 
which may impact on study quality and diagnostic accuracy. Further exploration of how co-
morbidity influences patients' experience of cancer staging and treatment is therefore 
important to maximise survival.  High deprivation was associated with increased WB-MRI 
burden in the unadjusted analysis. Deprivation is associated with higher cancer incidence and 
mortality, particularly for lung cancer,
31
 in addition to decreased engagement with cancer 
screening programmes.
32
 Further work to understand how deprivation influences perceived 
burden is important to improve experience and engagement.  
Our study does have limitations. Patients recruited to the Streamline trials volunteered to take 
part in our questionnaire study. The proportion of patients who completed the scan 
experience questions was arguably quite low at 54%. However this is in line with postal 
survey completion rates observed in other similar studies.
33
 We did consider issuing 
reminders to patients to increase response rate, but decided against this so as to not increase 
patient burden at a difficult time: patients had to complete and return two questionnaires 
within one month of a new cancer diagnosis. Although those who took part seem 
representative of Streamline trial participants overall (judged by our comparisons of 
registered and recruited patients), our sample may not represent all patients who may undergo 
WB-MRI in daily clinical practice. Patients in our study were relatively young compared to 
the typical age of diagnosis with lung or colorectal cancer and it is possible that scan 
acceptability is greater in younger patients. However, the study was done within the context 
of a large multi-institution study of WB-MRI, and the results are very likely to representative 
   
   
of most NHS institutions. The study was powered to detect clinically meaningful differences 
in perceptions of burden generated by WB-MRI and standard scans, while the power 
calculation prior to the start of the study assumed we would be using paired samples t-tests 
rather than Wilcoxon signed rank tests, significant differences were still detected with the 
latter. Other studies have used much larger numbers to try and predict poor tolerance of 
MRI.
8
 It is possible our null findings for some predictors (e.g. age, gender and cancer type) 
and findings of borderline significance for the role of deprivation in adjusted analyses, may 
be due to lack of statistical power to detect small effects.  Patients were asked to complete the 
baseline questionnaire at the point of trial registration, with the post-staging questionnaire 
one month later. Scan timing meant that at baseline some patients had already completed 
WB-MRI by the time they completed the baseline questionnaire and a whole month had 
elapsed before they were asked to answer the post-scan evaluation questions. This may have 
introduced some recall bias into their responses. However, recalled experience some time 
after the event may have greater prediction for future health behaviours than immediate 
recollection.
34 
Some patients may have been aware of their diagnosis at the time of 
completing the baseline questionnaire, when distress levels were assessed. We did not ask 
people whether or not they knew their diagnosis at baseline, but rates of distress among 
people undergoing investigations for suspected cancer are similar to those among people with 
a confirmed diagnosis, so this is unlikely to have affected the results observed.
1
   
It would have been useful to quantify patient co-morbidity with scores such as the Charlson 
score.
35
 However such scores are time consuming and collection of complete and clean data 
was not possible with our resources. As noted in the methods however, self-report measures 
of comorbidity have been shown to be valid
17;18 
and offer a more cost-effective method of 
data collection than medical record-based measures. 
   
   
A further limitation is that our study focused on scan experience, and although a number of 
questions were asked about scan acceptability, recovery time, and satisfaction with 
information, communication and facilities we did not examine patient views about overall 
appointment time, or how they viewed the time in the scanner vs. the time waiting before and 
after the scan. However of note, satisfaction was very high for all these items, and did not 
differ between scans. 
 
Conclusions 
In conclusion, patients undergoing staging for lung or colorectal cancer found WB-MRI more 
burdensome than standard CT and PET-CT although absolute differences in burden scores 
were small; most patients found WB-MRI fairly or very acceptable. Our findings demonstrate 
that patients with medical co-morbidities, or with pre-existing high levels of psychological 
distress, tolerate WB-MRI less well, and may therefore benefit from additional support.  
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Table: 1: Demographic and psychological characteristics of participants who completed the 
post-staging questionnaire. Numbers are percent (n) unless otherwise specified. 
 Overall Patient cohort 
Differences between 
patient cohorts 
 N=115 L
1
 n=54 C 
2
 n=61  
Demographic characteristics  
Age 
α
 (median in 
years (range)) 
66.3 (31-89) 69.7 (50-89)
 
64.2 (31-85) 
Mann Whitney U test 
p=0.010 
Male gender  
α
  58.3 (67) 55.6 (30) 60.7(37) X
2
=0.306; df=1; p=0.580 
White ethnicity 
φ  
91.8 (90) 93.8 (45) 90.0 (45) Fisher’s Exact;  p=0.715  
IMD deprivation
 α 
    
1 (highest) 23.5 (27) 25.9 (14) 21.3 (13) 
X
2=
0.3875;df=4; p=0.423 
2 24.3 (28) 27.8 (15) 21.3 (13) 
3 21.7 (25) 24.1 (13) 19.7 (12) 
4 17.4 (20) 14.8 (8) 19.7 (12) 
5 (lowest) 13.0 (15) 7.4 (4) 18.0 (11) 
Physical and emotional wellbeing 
Co-morbidity (at 
least one comorbid 
illness reported)
 φ   
53.4 (55) 66.7 (34) 40.4 (21) X
2
=7.147;df=1; p=0.008 
Emotional distress
φ 
(GHQ-12 score of 
4 or higher)
 
 
41.6 (42) 47.1 (24) 36.0 (18) X
2
=1.271;df=1; p=0.260 
1
 Non-small cell lung cancer 
2
 colorectal cancer  % is valid percent where there is missing 
data  
α 
No missing data 
ϩ 
Missing data less than 5% 
φ 
Missing data greater than 5% 
   
   
Table 2: Comparative experience of WB-MRI vs CT/PET-CT. Numbers are percent (n). 
 
Overall Lung (L) 
1
  Colorectal (C)  
2
  
Group differences 
(Wilcoxon sign test) 
Recovery time     
WB-MRI 
φ
    
a 
p=0.465 
b
p=0.735 
 
Immediate  63.9 (69) 61.5 (32)
a 
66.1 (37)
b 
Up to 30 minutes 25.9 (28) 23.1 (12) 28.6 (16) 
Over 30 minutes 10.2 (11) 15.4 (8) 5.4 (3) 
CT / PET-CT
φ
    
Immediate 65.1 (69) 58.8 (30)
a 
70.9 (39)
b 
Up to 30 minutes 21.7 (23) 23.5 (12) 20.0 (11) 
Over 30 minutes 13.2 (14) 17.6 (9) 9.1 (5) 
Acceptability     
WB-MRI
 φ
     
Very 65.2 (73) 64.8 (35)
a
 65.5 (38)
b
 
a 
p=0.035 
b
 p=0.005 
 
Fairly 30.4 (34) 29.6 (16) 31.0 (18) 
Slightly 3.6 (4) 3.7 (2) 3.4 (2) 
Not at all 0.9 (1) 1.9 (1) 0.0 (0) 
CT / PET-CT
 φ
    
Very 77.8 (84) 75.0 (39)
a
 80.4 (45)
b
 
Fairly 21.3 (23) 23.1 (12) 19.6 (11) 
Slightly 0.0 (0) 0.0 (0) 0.0 (0) 
Not at all 0.9 (1) 1.9 (1) 0.0 (0) 
 
 
   
   
Satisfied with information received before scan 
WB-MRI
 φ
     
Very satisfied 55.6 (60) 51.9 (27)
a 
58.9 (33)
b 
a 
p= 0.169 
b
 p= 0.071 
 
Satisfied 37.0 (40) 40.4 (21) 33.9 (19) 
Dissatisfied 3.7 (4) 5.8 (3) 1.8 (1) 
Very dissatisfied 3.7 (4) 1.9 (1) 5.4 (3) 
CT / PET-CT
 φ
    
Very satisfied 57.5 (61) 49.0 (25)
a 
65.5 (36)
b 
Satisfied 34.9 (37) 37.3 (19) 32.7 (18) 
Dissatisfied 0.9 (1) 2.0 (1) 0 (0) 
Very dissatisfied 6.6 (7) 11.8 (6) 1.8 (1) 
 Satisfied with communication during scan 
WB-MRI
 φ
     
Very satisfied 56.1 (60) 57.7 (30)
a 
54.5 (30)
b 
a 
p=0.637 
b
 p=0.059 
 
Satisfied 39.3 (42) 34.6 (18) 43.6 (24) 
Dissatisfied 2.8 (3) 5.8 (3) 0 (0) 
Very dissatisfied 1.9 (2) 1.9 (1) 1.8 (1) 
CT / PET-CT
 φ
    
Very satisfied 64.2 (68) 62.7 (32)
a 
65.5 (36)
b 
Satisfied 32.1 (34) 31.4 (16) 32.7 (18) 
Dissatisfied 1.9 (2) 3.9 (2) 0 (0) 
Very dissatisfied 1.9 (2) 2.0 (1) 1.8 (1) 
 
  
   
   
 
Satisfaction with facilities 
WB-MRI
 φ
     
Very satisfied 45.8 (49) 49.0 (25)
a 
42.9 (24)
b 
a 
p=0.225 
b
 p=0.480 
 
Satisfied 45.8 (49) 43.1 (22) 48.2 (27) 
Dissatisfied 4.7 (5) 2.0 (1) 7.1 (4) 
Very dissatisfied 3.7 (4) 5.9 (3) 1.8 (1) 
CT / PET-CT
 φ
    
Very satisfied 54.7 (58) 62.7 (32)
a 
47.3 (26)
b 
Satisfied 38.7 (41) 33.3 (17) 43.6 (24) 
Dissatisfied 4.7 (5) 2.0 (1) 7.3 (4) 
Very dissatisfied 1.9 (2) 2.0 (1) 1.8 (1) 
1
 Non-small cell lung cancer, WB-MRI vs. PET-CT 
2
 Colorectal cancer, WB-MRI vs CT.   
φ 
Missing data greater than 5%.  % is valid percent. 
 
 
 
 
 
 
 
 
   
   
Table 3: Comparative scan burden (WB-MRI vs CT/PET-CT). Numbers are mean (SD). 
 Overall L
1
 cohort  C 
2
 cohort 
Group differences using 
Wilcoxon signed rank test 
Total patient burden (scores 1-7)   
WB-MRI
 φ
 2.21 (1.1) 2.33
a 
(0.94) 2.09
b 
(1.18) 
a 
p<0.001 
CT/PET-CT
 φ
 1.87 (0.98) 2.05
a 
(0.82) 1.70
b 
(1.1) 
b
 p<0.001 
Discomfort sub-scale (1-7) 
WB-MRI
 φ 
2.51 (1.26) 2.65
a 
(1.14) 2.30
b 
(1.22) 
a
 p<0.001 
CT /PET-CT
 φ
 1.83 (1.05) 2.04
a 
 (.90) 1.63
b 
(1.15) 
b
 p<0.001 
Worry subscale (1-7) 
WB-MRI
 φ 
2.47 (1.32) 2.62
a 
(1.15) 2.23
 b 
(1.31) 
a
 p=0.208 
CT / PET-CT
 φ
 2.24 (1.23) 2.52
a 
(1.15) 2.00
 b 
(1.28) 
b 
p=0.041 
Satisfaction subscale (1-7) 
WB-MRI
 φ
 6.25
i 
(1.06) 6.27
a 
(0.85) 6.26
b 
(1.23) 
a
 p=0.036 
CT / PET-CT
 φ
 6.49
i 
(0.89) 6.43
a 
(0.76) 6.53
b 
(1.01) 
b
 p<0.001 
 
1
 Non-small cell lung cancer, WB-MRI vs. PET-CT  
2
 Colorectal cancer, WB-MRI vs CT.   
φ 
Missing data greater than 5%   
 
 
   
   
Figure One: flow diagram of participants through the study (March 2013 – July 2015) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Sent questionnaires at both time 
points  
n=214  
(C=55.1%,118  
L=44.9%, 96) 
 
 
 
 
 
 
 
Completed baseline 
questionnaire only  
n =27  
Completed post-
staging questionnaire 
only (no baseline data) 
n=12  
(C=9, L=3) 
Completed baseline 
and post-staging 
questionnaires   
n=104 
(C=52, L=52) 
 
Did not consent to questionnaire 
study 
n=42 
Consented to interview and/or 
questionnaire study n=350  
Response rate = 89.3%  
(‘L’=93.1%; ‘C’=85.8%) 
 
 
 
 
 
 
No response   
n=71 
n=91 recruited to interview 
study  
 
n=3 not sent baseline 
questionnaires* 
 
n=42 sent baseline 
questionnaire only * 
 
Recruited to trials during the period 
the questionnaire study was active 
N=392 
n=103 included  
n=1 withdrawn (didn’t have WB-
MRI) 
Included in analyses 
n=115  
(54% of those sent both 
questionnaires;  
C=53%, 61, L=47%, 54) 
 
* Reasons for withdrawal/ not 
sent follow up questionnaires  
n= 2 patient withdrew consent 
n=12 did not meet colorectal or 
non-small cell cancer inclusion 
criteria 
n=27 WB-MRI did not take place 
n= 3 not recruited to 
questionnaire study in error 
n=1 lost to follow up as moved 
abroad 
   
   
Appendix A: 26 items for Patient Burden Scale and sub-scales (* new items for this study) 
Satisfaction Sub-Scale (7 items) α=0.88 (WB-MRI), =0.84 (Pet/CT), =0.94 (CT) 
1. I was not interested vs. I was interested 
2. Loss of modesty vs. No loss of modesty 
3. Not confident in staff vs. Confident in the staff 
4. I was not pleased with how it went vs I was pleased with how it went 
5. Undignified vs. dignified 
6. Dissatisfied vs satisfied 
7. Not enough privacy vs Enough privacy 
Worry Sub-Scale (6 items)α=0.79(WB-MRI), =0.76 (Pet/CT), =0.86 (CT) 
8. Worried vs. not worried 
9. Agitated vs. Calm 
10. Did not understand what was happening vs. Understood what was happening 
11. I was worried about what they would find vs. I was not worried about what they would 
find 
12. I was confused vs. I was not confused 
13. I felt puzzled vs. I did not feel puzzled 
Physical Discomfort Sub-Scale (13 items)α=0.91 (WB-MRI), =0.88 (Pet/CT), =0.97 (CT) 
14. Felt out of control vs Felt in control 
   
   
15. Uncomfortable vs Comfortable 
16. The noise of the scanner was unbearable vs the noise of the scanner was fine * 
17. Difficult to do what was required vs. Easy to do what was required  
18. Tired afterwards not tired afterwards 
19. The need to repeatedly hold my breath was unbearable vs. the need to hold my breath was 
fine* 
20. A bad experience vs. a good experience 
21. The time the scan took was unbearable vs The time the scan took was fine* 
22. Claustrophobic vs. not claustrophobic 
23. The injections needed for the scan were unbearable vs the injections needed for the scan 
were fine* 
24. Undesirable side effects vs no undesirable side effects* 
25. Hard to cope with vs easy to cope with 
26. The need to lie still for the scan was unbearable vs the need to lie still for the scan was 
fine* 
 
  
   
   
Appendix B: On-line Table 1: Comparison of demographic characteristics of patients who did 
or did not consent to participate in the questionnaire study 
 
 Consent to questionnaire study 
Grp diff  No Consent 
n=42 
Consent 
n=350 
Age 
(median in years 
(range)) 
 
65.0  (36-96) 66.0  (29-94) 
 
Mann Whitney U 
test p=0.585 
Gender 
(% (n)) 
   
X
2 
=1.286, df=1; 
p=0.257 
Male 9.3 (23) 90.7 (223) 
Female 13.0 (19) 87.0 (127) 
Stream 
(% (n)) 
   
X
2 
=5.451, df=1; 
p=0.020 
Colorectal 14.2 (29) 85.8 (175) 
Lung 6.9 (13) 93.1 (175) 
Deprivation 
Quintile 
(% (n)) 
 
  
X
2
1.529, df=4; 
p=0.832 
1 (highest) 
 
40.5 (17) 31.7 (111) 
2 
 
23.8 (10) 28.0 (98) 
3 
 
14.3 (6) 16.6 (58) 
4 
 
14.3 (6) 13.1 (46) 
5 (Lowest) 
 
7.1 (3) 10.6 (37) 
 
 
 
  
   
   
Appendix C: On-line Table 2: Comparison of demographic characteristics of patients sent 
both questionnaires, who were or were not included in the final analysis  
 
 Sent both questionnaires  
Grp diff 
 Excluded from 
analysis 
n=99 
Included in final 
analysis 
n=115 
Age 
(median in years 
(range)) 
 
65.0 (30-86) 
 
66.3 (31-89) 
 
Mann Whitney 
U test p=0.676 
 
Gender 
(% (n)) 
  
X
2 
=3.578, df=1; 
p=0.059 Male 37.7 (29) 51.1 (70) 
Female 62.3 (48) 48.9 (67) 
Stream 
(% (n)) 
  
X
2 
=0.442, df=1; 
p=0.506 Colorectal 48.3 (57) 43.8 (42) 
Lung 56.3 (54) 51.7 (61) 
Deprivation 
Quintile 
(% (n)) 
 
  
X
2=
10.370, df=4; 
p=0.035 
1 (highest) 
 
60.9 (42) 39.1 (27) 
2 
 
45.1 (23) 54.9 (28) 
3 
 
32.4 (12) 67.6 (25) 
4 
 
41.2 (14) 58.8 (20) 
5 (Lowest) 
 
34.8 (8) 65.2 (15) 
 
 
 
 
 
 
 
 
